首页 >  专业园地 >  文献导读 >  临床观察 > 正文

哮喘小鼠模型中,阴地蕨提取物通过调节Th1/Th2平衡和白三烯受体表达水平发挥平喘功能

2013/10/11

   摘要
   研究目的:阴地蕨(ST),一种常见中草药,被用于治疗过敏性哮喘和百日咳。本研究中,我们在过敏性哮喘小鼠模型中研究ST治疗后外周血Th1/Th2细胞比和白三烯受体mRNA水平。
   材料和方法:通过卵白蛋白(OVA)致敏后吸入过敏原气溶胶构建哮喘小鼠模型。活性对照药物为孟鲁司特(10mg/kg),治疗组OVA致敏6天前开始给予ST治疗10天。通过Medlab 12.0生物信号处理系统评估气道反应,通过流式细胞仪检测Th1/Th2细胞比,使用PCR法检测Cyslt1表达水平,H&E染色法检测肺组织病理变化。
   结果:ST显著降低气道反应性,升高Th1/Th2细胞比,对Cyslt1 mRNA水平的降低作用呈现剂量-依赖性。高剂量ST可明显预防肺组织病理变化。
   结论:在哮喘小鼠模型中,高剂量ST具有和Montelukast相同的疗效,ST是一个抗哮喘的潜力药物。


 

(苏楠 审校)
JEthnopharmacol.2013Aug8.pii:S0378-8741(13)00533-3.doi:10.1016/j.jep.2013.07.032. [Epub ahead of print]


 


Sceptridium Ternatum extract exerts antiasthmatic effects by regulating Th1/Th2 balance and the expression levels of leukotriene receptors in a mouse asthma model.
 

Yuan Y, Yang B, Ye Z, Zhang M, Yang X, Xin C, Lin M, Huang P.
 

Abstract
AIM OF THE STUDY:
Sceptridium ternatum Lyon (ST), a common Chinese herb, has been used in treatment of allergic asthma and whooping cough. In the present study, we investigated the Th1/Th2 ratio of peripheral blood and mRNA levels of leukotriene receptors after the treatment of ST in allergic asthma mouse model.
MATERIALS AND METHODS: Mouse asthma model was developed by ovalbumin (OVA) sensitization followed by the inhalation of aerosol allergen. Montelukast (10mg/kg), as a positive control drug, and ST were administrated six days before the OVA sensitization for ten days. Airway responsiveness was evaluated by the Medlab 12.0 biological signal processing system. The ratio of Th1/Th2 cells was determined by flow cytometry. The expression level of Cyslt1 was measured by PCR. Pathological changes of lung tissues were examined by H&E staining.
RESULTS: ST significantly reduced the airway responsiveness, elevated the ratio of Th1/Th2, and decreased Cyslt1 mRNA level in a dose-dependent manner. High-dose ST distinctly prevented the pathological changes of lung tissues.
CONCLUSION: High-dose ST had the same efficacy as Montelukast in a mouse asthma model, and ST could be a potential anti-asthmatic agent.

 

JEthnopharmacol.2013Aug8.pii:S0378-8741(13)00533-3.doi:10.1016/j.jep.2013.07.032. [Epub ahead of print]


上一篇: 激素抵抗性哮喘:比看上去更复杂
下一篇: 15岁以下的新西兰儿童哮喘治疗方案和疗效存在种族差异:国家数据库的分析

用户登录